WESTLAKE VILLAGE, Calif. and ORLANDO, Fla., March 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT) (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing ...

A session held at the American Academy of Dermatology Annual Meeting 2024 highlighted the ways in which atopic dermatitis can be treated and addressed in adults and older adults. This content was ...

Add Yahoo as a preferred source to see more of our stories on Google. Considered in the past to be primarily a children's condition, atopic dermatitis can affect people of all ages If you’re over 60 ...

Any new medical diagnosis can be a lot to process, and atopic dermatitis is no exception. “It can come as quite a shock to suddenly develop eczema as an adult,” says Martin Smith, MD, a double board ...

Arcutis Biotherapeutics will present two significant posters at the 2025 American Academy of Dermatology annual meeting, showcasing data that reinforces the efficacy and safety of ZORYVE treatments in ...

Data from the INTEGUMENT trials demonstrates that ZORYVE cream 0.15% has a favorable safety profile and high tolerability, even among patients with prior inadequate responses to traditional treatments ...

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.

Repeated-measures modeling found no consistent links between active atopic dermatitis and BMI, blood pressure, lipid profiles ...

Nektar Therapeutics (Nasdaq: NKTR) announced today that data from the ongoing Phase 2b studies of rezpegaldesleukin in atopic ...

Many people experience an itchy scalp at some point. It’s usually not a sign of a serious medical condition and can, in most cases, be successfully treated with home remedies, over-the-counter ...

Both children and adults with atopic dermatitis have an increased risk of inflammatory bowel disease (IBD), according to a population-based cohort study. In fully adjusted models, kids with atopic ...